All In Biotech

Drug Trial Radar · NCT06890598

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Mar 27, 2025

Primary completion

May 2029

Study completion Feb 2032

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • OlomorasibDrug

    Administered orally.

  • PembrolizumabDrug

    Administered intravenously (IV).

  • DurvalumabDrug

    Administered IV.

  • PlaceboDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Disease-Free Survival (DFS) by Investigator AssessmentTime frame: Randomization to disease recurrence or death from any cause (Estimated as approximately 4 years).
  2. Part B: Progression-Free Survival (PFS) by BICRTime frame: Randomization to disease progression or death from any cause (Estimated as approximately 3 years).

Locations

368 sites in 29 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama · Recruiting

  • Infirmary Cancer Care

    Mobile, Alabama · Not yet recruiting

  • City of Hope, Phoenix

    Phoenix, Arizona · Not yet recruiting

  • The University of Arizona Cancer Center - North Campus

    Tucson, Arizona · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • City of Hope, Duarte

    Duarte, California · Not yet recruiting

  • City of Hope Lennar

    Irvine, California · Not yet recruiting

  • UCLA Hematology/Oncology - Santa Monica

    Los Angeles, California · Recruiting

  • Profound Research LLC

    Oceanside, California · Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center

    Orange, California · Recruiting

  • Stanford Cancer Center

    Palo Alto, California · Recruiting

  • Kaiser Permanente San Diego Mission Road

    San Diego, California · Recruiting

  • BASS Cancer Center

    Walnut Creek, California · Recruiting

  • Hartford Hospital (HH)

    Hartford, Connecticut · Recruiting

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • Boca Raton Regional Hospital

    Boca Raton, Florida · Recruiting

  • Florida Cancer Specialists - South

    Fort Myers, Florida · Recruiting

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida · Recruiting

  • Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala

    Ocala, Florida · Recruiting

  • Florida Cancer Specialists North

    St. Petersburg, Florida · Recruiting

  • Comprehensive Hematology Oncology

    St. Petersburg, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Florida Cancer Specialists East

    West Palm Beach, Florida · Recruiting

  • University Cancer & Blood Center, LLC

    Athens, Georgia · Recruiting

  • Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • City of Hope National Medical Center, Atlanta Cancer Center

    Newnan, Georgia · Not yet recruiting

  • City of Hope, Chicago

    Chicago, Illinois · Not yet recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Suspended

  • University of Illinois at Chicago

    Chicago, Illinois · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Captain James A. Lovell Federal Health Care Center

    North Chicago, Illinois · Recruiting

  • OSF Saint Francis Medical Center

    Peoria, Illinois · Not yet recruiting

  • Springfield Clinic Main Campus

    Springfield, Illinois · Recruiting

  • Parkview Research Center at Parkview Regional Medical Center

    Fort Wayne, Indiana · Recruiting

  • Franciscan Health

    Indianapolis, Indiana · Recruiting

  • Baptist Health Lexington

    Lexington, Kentucky · Recruiting

  • Baptist Health Hamburg

    Lexington, Kentucky · Recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Recruiting

  • Ochsner Health Ochsner Cancer Center - Baton Rouge

    Baton Rouge, Louisiana · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Recruiting

Showing 40 of 368 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.